Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines

Advanced or recurrent low-grade serous ovarian cancers (LGSC) are resistant to conventional systemic treatments. LGSC carry mutations in RAS or RAF, leading to several clinical trials evaluating MEK inhibitors (MEKi). As LGSC cell lines and xenografts have been difficult to establish, little is know...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Am J Cancer Res
Hoofdauteurs: Fernández, Marta Llauradó, DiMattia, Gabriel E, Dawson, Amy, Bamford, Sylvia, Anderson, Shawn, Hennessy, Bryan T, Anglesio, Michael S, Shepherd, Trevor G, Salamanca, Clara, Hoenisch, Josh, Tinker, Anna, Huntsman, David G, Carey, Mark S
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: e-Century Publishing Corporation 2016
Onderwerpen:
Original Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5088288/
https://ncbi.nlm.nih.gov/pubmed/27822414
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items